The Food and Drug Administration has a lot on its plate over the next three months.
The agency may soon issue a decision that could greatly boost access to an Alzheimer’s medicine that’s been hampered by a strict Medicare coverage policy. The regulator could also clear a new type of depression drug and another option against a common respiratory infection. Two advisory meetings are on deck as well, each involving much-debated clinical trial results.
